Abstract 144P
Background
Patients with squamous NSCLC have a poorer prognosis than those with non-squamous histology and fewer treatment options. The phase 3 EMPOWER-Lung 1 study (NCT03088540) has demonstrated significant survival benefits of first-line (1L) cemiplimab monotherapy vs chemotherapy and an acceptable safety profile in patients with treatment-naïve squamous or non-squamous NSCLC with PD-L1 expression ≥50% and no EGFR, ALK or ROS1 aberrations. Here, we report 5-year results of patients with squamous NSCLC from this study.
Methods
In EMPOWER-Lung 1, patients were randomized to cemiplimab 350 mg IV every 3 weeks for 2 years or to investigator’s choice of chemotherapy. Primary endpoints were overall survival (OS) and progression-free survival (PFS) per Blinded Independent Review Committee. In this exploratory subgroup analysis, efficacy and safety were assessed for the subgroup of patients with squamous NSCLC. The data cutoff date was 16 January 2024 (median follow-up of 59.6 months for the overall study population).
Results
Of 565 patients with verified PD-L1 ≥50%, 245 (43%) had squamous NSCLC (cemiplimab: n = 123; chemotherapy: n = 122). Baseline characteristics were similar between treatment groups. At 5-year follow-up, cemiplimab resulted in longer OS (median 22.7 mo vs 13.5 mo; HR=0.51) and PFS (median 8.3 mo vs 5.9 mo; HR=0.44) vs chemotherapy (Table). Estimated 5-year survival probability was 25.5% for cemiplimab vs 6.9% for chemotherapy. Objective response rate (ORR) was significantly improved with cemiplimab (43.9% vs 22.1%). Approximately 42% of patients in both treatment groups had treatment-emergent adverse events (TEAEs) ≥ grade 3 (Table). Table: 144P
Cemiplimab (n=123)† | Chemotherapy (n=122)† | |
Clinical outcomes | ||
OS median (95% CI), mo | 22.7 (17.3–31.5) | 13.5 (10.0–16.2) |
HR (95% CI) | 0.51 (0.38–0.69)* | |
5-year probability OS, % (95% CI) | 25.5 (17.3–34.5) | 6.9 (2.8–13.6) |
PFS median (95% CI), mo | 8.3 (5.6–9.4) | 5.9 (4.5–6.2) |
HR (95% CI) | 0.44 (0.32–0.60)* | |
ORR, % (95% CI) | 43.9 (35.0–53.1) | 22.1 (15.1–30.5) |
Safety outcomes‡ | ||
TEAEs of any grade, n (%) | 110 (90.2) | 111 (94.1) |
Grade ≥3 TEAEs, n (%) | 51 (41.8) | 50 (42.4) |
†Subgroup from the PD-L1 ≥50% population. ‡Safety analysis set for the subgroup: cemiplimab (n=122), chemotherapy (n=118). ∗P<0.0001
Conclusions
At 5-year follow-up, 1L cemiplimab monotherapy continued to show durable clinical benefits vs chemotherapy in patients with squamous NSCLC.
Clinical trial identification
NCT03088540.
Editorial acknowledgement
Editorial support was provided by Fiona Woodward, of Alpha (a division of Prime, Knutsford, UK) funded by Regeneron Pharmaceuticals, Inc., and Sanofi. Responsibility for all opinions, conclusions, and data interpretation lies with the authors.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc.
Funding
Regeneron Pharmaceuticals, Inc.
Disclosure
A. Baramidze: Financial Interests, Personal, Other, Travel support: Regeneron Pharmaceuticals, Inc. A. Sezer: Financial Interests, Institutional, Research Funding: Roche, Merck Sharp & Dohme, Merck Serono, AstraZeneca, Lilly, Novartis, Johnson & Johnson, Regeneron Pharmaceuticals, Inc., Sanofi. M. Gumus: Financial Interests, Personal, Other, Honoraria: Roche, Merck Sharp & Dohme, Gen İlaç, Novartis. K.D. Penkov: Financial Interests, Personal, Other, Honoraria: AstraZeneca, BeiGene, GSK, H3 Biomedicine, Janssen, Nektar, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi. M. Ozguroglu: Financial Interests, Personal, Other, Honoraria: Novartis, Roche, Janssen, Sanofi, Astellas; Financial Interests, Personal, Advisory Board: Janssen, Sanofi, Astellas; Financial Interests, Personal, Other, Travel support: Bristol Myers Squibb, Janssen, AstraZeneca; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca. E. Kalinka: Financial Interests, Personal, Other, Travel and accommodation support: Regeneron Pharmaceuticals, Inc. C. Zhu, F. Seebach, E. Kim, H. Magnan, J. Pouliot: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
226P - Profiling of gastric adenocarcinomas from EU and LATAM countries identifies distinct tumor immune subgroups and a central role of the tumor microbiome in shaping the immune microenvironment
Presenter: Manuel Cabeza Segura
Session: Poster Display session
Resources:
Abstract
228P - Modulating mitochondrial dynamics in TAMs to enhance anti-tumor immunity
Presenter: Pu-ste Liu
Session: Poster Display session
Resources:
Abstract
229P - Investigation of the effects of long-noncoding RNA NRAV on interferon response in melanoma
Presenter: Kadir Durmus
Session: Poster Display session
Resources:
Abstract
230P - Deciphering the mechanism of immunosuppressive activity of acetaminophen in the context of cancer immunotherapy
Presenter: Jeanne Lena
Session: Poster Display session
Resources:
Abstract
231P - The impact of calcitriol and tacalcitol on the Th17 lymphocytes in breast cancer
Presenter: Beata Filip-Psurska
Session: Poster Display session
Resources:
Abstract